OTCMKTS:NVZMF Novozymes A/S - NVZMF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novozymes A/S Please log in to your account or sign up in order to add this asset to your watchlist. $50.86 0.00 (0.00%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$50.86▼$50.8650-Day Range$48.37▼$60.9252-Week Range$38.16▼$70.50Volume200 shsAverage Volume5,580 shsMarket CapitalizationN/AP/E Ratio6.34Dividend Yield0.72%Price TargetN/A ProfileChartCompetitorsFinancialsHeadlinesSEC FilingsShort Interest Novozymes A/S MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearishDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.61Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.89 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Novozymes A/S. Previous Next 0.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverNovozymes A/S has a short interest ratio ("days to cover") of 339.2, which indicates bearish sentiment.Change versus previous monthShort interest in Novozymes A/S has recently increased by 4.26%, indicating that investor sentiment is decreasing. Previous Next 0.8 Dividend Strength Dividend YieldNovozymes A/S has a dividend yield of 0.72%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthNovozymes A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novozymes A/S is 22.44%. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVZMF. Previous Next 2.0 News and Social Media Coverage News SentimentNovozymes A/S has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Novozymes A/S this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novozymes A/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 20.41% of the stock of Novozymes A/S is held by institutions. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Novozymes A/S is 6.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 147.18.Price to Earnings Ratio vs. SectorThe P/E ratio of Novozymes A/S is 6.34, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 158.85. Previous Next See Top Rated MarketRank™ Stocks Here About Novozymes A/S (OTCMKTS:NVZMF) StockNovozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark.Read More Receive NVZMF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address NVZMF Stock News HeadlinesJanuary 25, 2023 | edition.cnn.comEU red tape creates ‘roadblocks’ on sustainability, says Novozymes bossJanuary 12, 2023 | finance.yahoo.comNovozymes A/S (NVZMF)February 1, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 12, 2022 | msn.comNovozymes is set to merge with Chr. Hansen as part of a historic dealNovember 5, 2022 | seekingalpha.comNovozymes A/S (NVZMF) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | finance.yahoo.comNovozymes confirms upgraded guidance by strong start to Q4November 1, 2022 | finance.yahoo.comNovozymes Named EPA Safer Choice Partner of the Year for Second Consecutive YearAugust 14, 2022 | seekingalpha.comNovozymes A/S 2022 Q1 - Results - Earnings Call PresentationFebruary 1, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.August 11, 2022 | finance.yahoo.comNovozymes delivers strong half year results and narrows full-year outlook upwardsJuly 15, 2022 | finance.yahoo.comNovozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming costJune 7, 2022 | finance.yahoo.comNovozymes extends the lifetime of textiles with sustainable innovationApril 27, 2022 | seekingalpha.comNovozymes A/S (NVZMF) CEO Ester Baiget on Q1 2022 Results - Earnings Call TranscriptApril 26, 2022 | finance.yahoo.comNovozymes delivers strong 2022 Q1 results and raises full-year financial guidanceJanuary 18, 2022 | nasdaq.comNovozymes AS - Class B (NVZMF)December 16, 2021 | finance.yahoo.comClosing the gap between sustainability and profits in corn wet millingDecember 16, 2021 | finance.yahoo.comMarrone Bio Optimizes Bioherbicide with New Bacteria Strains, Accelerates Product Development to Enter $27 Billion Herbicide Market¹December 13, 2021 | finance.yahoo.comNovozymes and Saipem enter collaboration agreement to create a more sustainable CO2 captureSeptember 26, 2021 | markets.businessinsider.comNovozymes A/S : Novozymes is combining cutting-edge science and business expertise to help feed the world sustainablyAugust 31, 2021 | finanznachrichten.deNovozymes Bioenergy Business Threatened by Electric Cars, Bank of America SaysAugust 12, 2021 | finance.yahoo.comNovozymes reaches a strategic milestone in the implementation of its strategy with a significant entry into Advanced Protein SolutionsAugust 12, 2021 | finance.yahoo.comInterim report for 1H 2021August 12, 2021 | finance.yahoo.comNovozymes delivers strong Q2 results and narrows full-year guidance to the high-end of the rangeMay 17, 2021 | finance.yahoo.comAXTA vs. NVZMY: Which Stock Should Value Investors Buy Now?April 29, 2021 | finance.yahoo.comCE vs. NVZMY: Which Stock Should Value Investors Buy Now?April 29, 2021 | finance.yahoo.comProfessional cleaning companies collaborate to evaluate the benefit of probiotics in green cleaning, in response to COVID-19April 29, 2021 | seekingalpha.comNovozymes A/S 2021 Q1 - Results - Earnings Call PresentationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NVZMF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address NVZMF Company Calendar Last Earnings4/20/2016Today1/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:NVZMF CUSIPN/A CIK1131345 Webwww.novozymes.com Phone(454) 446-0000FaxN/AEmployees6,184Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio6.34 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesEster BaigetPresident & Chief Executive OfficerGraziela Chaluppe dos Santos MalucelliChief Operating Officer & Executive VPLars GreenChief Financial Officer & Executive Vice PresidentClaus Crone FuglsangExecutive Vice President-Research & DevelopmentAnders LundEVP & Head-Consumer BiosolutionsKey Competitors3SBioOTCMKTS:TRSBFAbattis BioceuticalsOTCMKTS:ATTBFAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFAinosNASDAQ:AIMDWView All Competitors NVZMF Stock - Frequently Asked Questions How have NVZMF shares performed in 2023? Novozymes A/S's stock was trading at $50.36 on January 1st, 2023. Since then, NVZMF stock has increased by 1.0% and is now trading at $50.8550. View the best growth stocks for 2023 here. Are investors shorting Novozymes A/S? Novozymes A/S saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 2,732,700 shares, an increase of 41.2% from the December 31st total of 1,935,100 shares. Based on an average daily volume of 3,900 shares, the days-to-cover ratio is presently 700.7 days. View Novozymes A/S's Short Interest. How were Novozymes A/S's earnings last quarter? Novozymes A/S (OTCMKTS:NVZMF) posted its quarterly earnings data on Wednesday, April, 20th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $2.43 by $2.06. Is Novozymes A/S a good dividend stock? Novozymes A/S (OTCMKTS:NVZMF) pays an annual dividend of $1.80 per share and currently has a dividend yield of 0.72%. The dividend payout ratio is 22.44%. This payout ratio is at a healthy, sustainable level, below 75%. What is Novozymes A/S's stock symbol? Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMF." How do I buy shares of Novozymes A/S? Shares of NVZMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Novozymes A/S's stock price today? One share of NVZMF stock can currently be purchased for approximately $50.86. How many employees does Novozymes A/S have? The company employs 6,184 workers across the globe. How can I contact Novozymes A/S? Novozymes A/S's mailing address is Krogshoejvej 36, BAGSVAERD, 2880, Denmark. The official website for the company is www.novozymes.com. The biotechnology company can be reached via phone at (454) 446-0000. This page (OTCMKTS:NVZMF) was last updated on 2/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.